Citi analyst Stephanie Demko downgraded Allscripts to Neutral and lowered her price target for the shares to $12 from $14. The “implied steepness” in the ramp to long-term guidance “may prove out of reach,” while near-term challenges in investor sentiment could keep shares range bound, Demko tells investors in a post-earnings research note. She points out the stock traded down 11% as a miss on headline numbers and fiscal 2019 guidance “likely struck a raw nerve with investors” following management’s bullish tone in January.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.